

S/N 10/589443

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	FUKUMOTO et al.	Docket No.:	20039.0006USWO
Serial No.:	10/589443	Filed:	May 7, 2007
Patent No.:	7,842,701	Issued:	November 30, 2010
Title:	PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF		

CERTIFICATE OF TRANSMISSION.

I hereby certify that this paper is being transmitted by EFS Web to the United States Patent & Trademark Office on March 22, 2012.

By: 

Name: Chieko Rogers

REQUEST FOR CERTIFICATE OF CORRECTION

Mail Stop: Certificate of Correction
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

It is requested that a Certificate of Correction be issued correcting a typographical error appearing in the above-identified United States Patent and Certificate of Correction. A copy of the text of the Certificate in the suggested form is attached. The typographical error was made on the Form SB44, filed on January 25, 2012. Applicant requests that a renewed Certificate of Correction be issued to correct (supersede) the Certificate of Correction issued February 28, 2012.

Issuance of the Certificate of Correction would neither expand nor contract the scope of the claims, and re-examination is not required.

Please charge Deposit Account No. 50-3478 in the amount of \$100.00 to cover the required fee.



Dated: March 22, 2012

Respectfully submitted,

HAMRE, SCHUMANN, MUELLER &
LARSON, P.C.
P.O. Box 2902
Minneapolis, MN 55402-0902
(612) 455-3800

By: 

Douglas P. Mueller
Reg. No. 30,300
DPM/cmr

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7,842,701

APPLICATION NO.: 10/589443

ISSUE DATE : November 30, 2010

INVENTOR(S) : FUKUMOTO et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 238, lines 30-34 (claim 3): "...3-amino-2-(5-hydroxy-2-m ethylpenyl)-7-(3-morpholin-4-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one, 3-amino-2-(5-hydroxy-2-ylpropoxy)methylphenyl)-7-(2-morpholin-4-ylethoxy)-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one, or a salt thereof."

should read

-- ...3-amino-2-(5-hydroxy-2-methylpenyl)-7-(3-morpholin-4-ylpropoxy)-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one, 3-amino-2-(5-hydroxy-2-methylphenyl)-7-(2-morpholin-4-ylethoxy)-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one, or a salt thereof. --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

P.O. Box 2902
Minneapolis, MN 55402-0902

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.